Description_x000D_ Application_x000D_ 5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside has been used:_x000D_ • as an inhibitor of RNA polymerase II in mouse melanoma cells_x000D_ • for the inhibition of cyclin D1 mRNA synthesis in human prostate epithelial cell lines_x000D_ • in the inhibition of interleukin-2 gene transcription in Jurkat cells_x000D_ Packaging_x000D_ 10 mg in poly bottle_x000D_ 50 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ 5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB), a nucleoside analog that halts mRNA synthesis by phosphorylation of the C-terminal domain of RNA polymerase II, making it inactive. It also interferes with the DNA topoisomerase II, may modulate response to cytokines and blocks the human immunodeficiency virus (HIV) via RNA modification. It also inhibits cyclin-dependent kinases (CDKs) 7 and 9 and favors apoptosis in leukemic cells. It may serve as a therapeutic agent in treating cancer._x000D_ Inhibitor of RNA synthesis; causes premature termination of transcription. CK2 (casein kinase-2) inhibitor._x000D_ Features and Benefits_x000D_ This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm._x000D_ This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more._x000D_ Legal Information_x000D_ LOPAC is a registered trademark of Sigma-Aldrich Co. LLC